Antibody-drug conjugates in HER2-positive breast cancer.
10.1097/CM9.0000000000001932
- Author:
Lixi LI
1
;
Di ZHANG
;
Binliang LIU
;
Dan LV
;
Jingtong ZHAI
;
Xiuwen GUAN
;
Zongbi YI
;
Fei MA
Author Information
1. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- Publication Type:Review
- MeSH:
Antineoplastic Agents/therapeutic use*;
Antineoplastic Agents, Immunological/therapeutic use*;
Breast Neoplasms/drug therapy*;
Female;
Humans;
Immunoconjugates/therapeutic use*;
Receptor, ErbB-2
- From:
Chinese Medical Journal
2021;135(3):261-267
- CountryChina
- Language:English
-
Abstract:
Antibody-drug conjugates (ADCs) combine the high specificity of monoclonal antibodies with the high anti-tumor activity of small molecular cytotoxic payloads. The anti-tumor activity of ADCs is mainly achieved by the direct blocking of the receptor by monoclonal antibodies, direct action and bystander effect of cytotoxic drugs, and antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. ADCs have been used in adjuvant therapy and rescue treatment of human epidermal receptor 2 (HER2)-positive breast cancer, greatly improving the prognosis of breast cancer patients. Several ongoing clinical trials of ADC for breast cancer and other solid tumors proved the potential of ADCs will provide more promising treatment options for patients with malignant tumors. This review introduces the mechanism and latest clinical progress of ADC drugs approved for HER2-positive breast cancer to guide clinical practice and conduct research.
